Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on IFRX stock, giving a Buy rating yesterday.Stay Ahead of the ...
InflaRx N.V. IFRX shares gained 7.7% on Wednesday following the European Commission's (EC) approval of marketing ...
InflaRx (NASDAQ:IFRX) has received EU regulatory approval for its treatment Gohibic for the treatment of COVID-19 patients ...
H.C. Wainwright analyst Edward White reiterated a Buy rating on InflaRx (IFRX – Research Report) today and set a price target of $8.00.Stay ...
JENA, Germany, Jan. 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today ...
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary ...
Shares of InflaRx stock opened at $2.24 on Friday. InflaRx has a one year low of $1.16 and a one year high of $2.82. The company has a market cap of $131.90 million, a P/E ratio of -2.07 and a ...
InflaRx N.V.: InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904
JENA, Germany, Dec. 20, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced ...
JENA, Germany - InflaRx N.V. (NASDAQ:IFRX), a clinical-stage biopharmaceutical company, has announced the appointment of Jan Medina, CFA, as the new Vice President and Head of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback